Under the Medicare drug negotiations provisions in the reconciliation bill, the federal government would see its outlays reduced by about $300 billion. That reduction wouldn’t result from cuts in benefits. Instead, Medicare would be empowered to leverage its market power to pay lower prices for certain drugs.
A TV and social media ad offers a reason to check on the enforcement of a sweeping rule that requires hospitals to post information about what they charge insurers and cash-paying patients.
Her doctor told her the noninvasive genetic test would be $99. When she called, she was told $250 and if she didn’t pay quickly it could be $800.
The federal government is stepping in to assist student loan borrowers. But little public attention has been focused on what is — statistically, at least — a bigger, broader debt crisis in our country: An estimated 100 million people in the U.S., or 41% of all adults, are saddled with pernicious health care debt.
Debt lawsuits — long a byproduct of America’s medical debt crisis — can ensnare not only patients but also those who help sick and older people be admitted to nursing homes, a KHN-NPR investigation finds.
After a car wreck, three siblings were transported to the same hospital by ambulances from three separate districts. The sibling with the most minor injuries got the biggest bill.
Health insurers and self-insured employer plans are now required to post their negotiated rates for almost every type of medical service. But navigating through the trove of information is no easy task.
California Healthline senior correspondent Angela Hart describes California’s ambitious plan to manufacture generic insulin under the state’s new “CalRx” drug label.
The Elder Index, developed by researchers at the University of Massachusetts-Boston, shows that nearly 5 million older women living alone, 2 million older men living alone, and more than 2 million older couples have incomes that make them economically insecure.
Families affected by ultra-rare diseases are starting their own companies to speed the development of treatments for their kids, venturing into territory that traditional drugmakers deem too risky.
